Royalty Pharma plc (RPRX)

Royalty Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,350	2,264	2,355	2,237	2,289	2,122
Revenue Growth (YoY)	3.69%	-3.86%	5.24%	-2.28%	7.87%	16.98%
Cost of Revenue	-155.04	732.46	560.66	904.24	452.84	230.84
Gross Profit	2,505	1,531	1,794	1,333	1,837	1,892
Selling, General & Admin	448.37	236.67	249.75	227.3	182.83	181.72
Research & Development	402.5	2	52	177.11	200.08	26.29
Amortization of Goodwill & Intangibles	-	-	-	5.67	23	23.06
Operating Expenses	944.4	238.67	301.75	410.08	405.91	231.06
Operating Income	1,560	1,292	1,492	922.89	1,431	1,660
Interest Expense	-279.69	-225.51	-187.19	-187.96	-166.14	-167.96
Interest & Investment Income	28.65	47.34	72.29	78.34	53.54	28.38
Earnings From Equity Investments	56.79	29.61	28.88	-8.97	-19.49	44.46
Other Non Operating Income (Expenses)	63.21	-7.53	-24.03	81.86	-27.21	-33.5
EBT Excluding Unusual Items	1,429	1,136	1,382	886.15	1,271	1,532
Gain (Loss) on Sale of Investments	-98.03	194.46	317.98	-40.26	-30.21	265.67
Asset Writedown	-	-	-	-615.83	-	-65.05
Other Unusual Items	-	-	-	-	-	-30.5
Pretax Income	1,302	1,331	1,700	230.06	1,241	1,702
Earnings From Continuing Operations	1,302	1,331	1,700	230.06	1,241	1,702
Minority Interest in Earnings	-537.68	-471.83	-565.25	-187.23	-621.47	-726.91
Net Income	764.74	858.98	1,135	42.83	619.73	975.04
Preferred Dividends & Other Adjustments	-	-	-	-	-	479.84
Net Income to Common	764.74	858.98	1,135	42.83	619.73	495.2
Net Income Growth	-33.22%	-24.31%	2549.50%	-93.09%	-36.44%	-58.48%
Shares Outstanding (Basic)	466	448	448	438	415	375
Shares Outstanding (Diluted)	572	594	603	438	415	375
Shares Change (YoY)	-3.98%	-1.46%	37.66%	5.59%	10.48%	-
EPS (Basic)	1.64	1.92	2.54	0.10	1.49	1.32
EPS (Diluted)	1.60	1.91	2.53	0.10	1.49	1.32
EPS Growth	-37.18%	-24.54%	2490.74%	-93.44%	12.97%	-
Dividend Per Share	0.870	0.840	0.800	0.760	0.680	0.300
Dividend Growth	4.82%	5.00%	5.26%	11.77%	126.67%	-
Gross Margin	106.60%	67.64%	76.19%	59.58%	80.22%	89.12%
Operating Margin	66.40%	57.10%	63.37%	41.25%	62.49%	78.24%
Profit Margin	32.55%	37.95%	48.20%	1.92%	27.07%	23.33%
EBITDA	-	-	1,498	928.56	1,454	1,684
EBITDA Margin	-	-	63.61%	41.50%	63.50%	79.32%
D&A For EBITDA	-	-	5.67	5.67	23	23.06
EBIT	1,560	1,292	1,492	922.89	1,431	1,660
EBIT Margin	66.40%	57.10%	63.37%	41.25%	62.49%	78.24%
Revenue as Reported	2,350	2,264	2,355	2,237	2,289	2,122

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q